Rocket Pharmaceu Financials
Rocket Pharmaceu (RCKT) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rocket Pharmaceuticals remains a research-heavy, externally funded business, with cash burn driven by operating spend rather than debt service.
FY2025’s smaller net loss did not translate into balance-sheet relief: operating cash outflow stayed close to the accounting loss at-$190.0M versus net income of-$223.1M , while cash still fell to$77.6M because the financing bridge that supplied$185.7M in FY2024 shrank to just$148K . That combination shows prior years were being supported mainly by fresh capital rather than by the business naturally easing into cash preservation.
The cost base did improve, but the mechanism matters: R&D fell to
The balance sheet is still equity-funded rather than lender-funded, with liabilities of
Financial Health Signals
Rocket Pharmaceu does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Rocket Pharmaceu scores -3.49, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($385.3M) relative to total liabilities ($53.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Rocket Pharmaceu passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Rocket Pharmaceu reported a net loss of $223.1M while operations used $190.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Rocket Pharmaceu reported an operating loss of $231.7M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Rocket Pharmaceu generated $0 in revenue in fiscal year 2025.
Rocket Pharmaceu's EBITDA was -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.2% from the prior year.
Rocket Pharmaceu reported -$223.1M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Rocket Pharmaceu earned -$2.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 26.4% from the prior year.
Cash & Balance Sheet
Rocket Pharmaceu recorded an outflow of $190.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 11.7% from the prior year.
Rocket Pharmaceu held $77.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Rocket Pharmaceu's ROE was -80.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 24.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Rocket Pharmaceu invested $142.0M in research and development in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Rocket Pharmaceu invested $440K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 92.5% from the prior year.
Not reported for fiscal year 2025.
RCKT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| R&D Expenses | N/A | $142.0M-17.1% | $171.2M-8.1% | $186.3M+12.5% | $165.6M+32.0% | $125.5M+19.0% | $105.4M+82.1% | $57.9M+8.7% | $53.3M+257.1% | $14.9M+148.9% | $6.0M-52.3% | $12.6M+124.5% | $5.6M |
| SG&A Expenses | N/A | $86.5M-15.2% | $102.0M+39.1% | $73.3M+24.7% | $58.8M+40.7% | $41.8M+44.7% | $28.9M+58.2% | $18.2M+2.0% | $17.9M+268.4% | $4.9M+207.3% | $1.6M-79.9% | $7.8M+271.3% | $2.1M |
| Operating Income | N/A | -$231.7M+15.2% | -$273.2M-5.2% | -$259.7M-15.7% | -$224.3M-34.1% | -$167.2M-24.5% | -$134.3M-76.4% | -$76.2M-7.0% | -$71.2M-259.9% | -$19.8M-161.1% | -$7.6M+62.9% | -$20.4M-164.7% | -$7.7M |
| Interest Expense | N/A | $1.9M+0.3% | $1.9M+0.6% | $1.9M+0.7% | $1.9M-37.5% | $3.0M-57.3% | $7.0M+16.9% | $6.0M-1.3% | $6.0M | $0 | $0-100.0% | $1.2M+25.5% | $980K |
| Income Tax | N/A | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$223.1M+13.8% | -$258.7M-5.4% | -$245.6M-10.7% | -$221.9M-31.2% | -$169.1M-21.0% | -$139.7M-80.8% | -$77.3M-3.7% | -$74.5M-280.6% | -$19.6M-158.5% | -$7.6M+88.9% | -$68.0M-613.3% | -$9.5M |
| EPS (Diluted) | — | -$2.01+26.4% | -$2.73+6.5% | -$2.92+10.4% | -$3.26-22.1% | -$2.67-6.0% | -$2.52-59.5% | -$1.58 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RCKT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $330.4M-37.4% | $527.7M-6.8% | $566.3M+2.6% | $551.8M+11.0% | $497.0M-15.9% | $590.8M+58.8% | $372.1M+48.1% | $251.3M+1147.4% | $20.1M-84.5% | $129.6M+14.4% | $113.3M+1952.9% | $5.5M |
| Current Assets | $192.7M-49.0% | $378.2M0.0% | $378.2M+3.9% | $364.1M-7.1% | $392.1M-19.6% | $487.3M+58.4% | $307.8M+47.2% | $209.1M+1003.1% | $19.0M-85.2% | $128.3M+14.2% | $112.4M+2961.7% | $3.7M |
| Cash & Equivalents | $77.6M-52.6% | $163.6M+192.7% | $55.9M-60.2% | $140.5M-39.6% | $232.7M-21.7% | $297.1M+60.3% | $185.4M+66.5% | $111.4M+513.8% | $18.1M-39.1% | $29.8M-62.8% | $80.0M+2112.3% | $3.6M |
| Goodwill | $39.2M0.0% | $39.2M0.0% | $39.2M-0.1% | $39.2M+27.2% | $30.8M0.0% | $30.8M0.0% | $30.8M0.0% | $30.8M | $0 | N/A | N/A | N/A |
| Total Liabilities | $53.2M-17.4% | $64.5M-12.6% | $73.8M+18.7% | $62.1M+46.9% | $42.3M-51.6% | $87.3M+34.7% | $64.8M+13.2% | $57.3M+1137.6% | $4.6M-96.2% | $121.3M+24.0% | $97.8M+71.3% | $57.1M |
| Current Liabilities | $30.2M-25.8% | $40.7M-16.1% | $48.5M+23.8% | $39.2M+76.7% | $22.2M-32.0% | $32.6M+78.1% | $18.3M+19.1% | $15.4M+240.0% | $4.5M-35.8% | $7.0M+70.1% | $4.1M-42.7% | $7.2M |
| Total Equity | $277.2M-40.2% | $463.2M-6.0% | $492.6M+0.6% | $489.7M+7.7% | $454.7M-9.7% | $503.5M+63.9% | $307.3M+58.4% | $194.0M+1150.3% | $15.5M+85.4% | $8.4M-46.1% | $15.5M+130.1% | -$51.6M |
| Retained Earnings | -$1.4B-18.3% | -$1.2B-27.0% | -$959.4M-34.4% | -$713.8M-45.1% | -$491.9M-52.4% | -$322.8M-76.3% | -$183.1M-73.0% | -$105.9M-237.7% | -$31.4M+86.9% | -$238.9M-21.9% | -$196.0M-53.1% | -$128.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
RCKT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$170.3M | -$190.0M+9.4% | -$209.7M-7.6% | -$194.9M-9.4% | -$178.1M-47.0% | -$121.2M-62.3% | -$74.6M-15.4% | -$64.7M-20.2% | -$53.8M-237.0% | -$16.0M-190.1% | -$5.5M+68.4% | -$17.4M-78.8% | -$9.7M |
| Capital Expenditures | $127K | $440K-92.5% | $5.9M-64.3% | $16.4M+96.6% | $8.4M+9.7% | $7.6M-63.0% | $20.6M-11.4% | $23.3M+1501.4% | $1.5M+91.2% | $760K+126.9% | $335K-18.7% | $412K | N/A |
| Free Cash Flow | -$170.5M | -$190.5M+11.7% | -$215.6M-2.0% | -$211.4M-13.3% | -$186.5M-44.8% | -$128.8M-35.2% | -$95.2M-8.3% | -$87.9M-59.2% | -$55.2M-230.3% | -$16.7M-186.4% | -$5.8M+67.3% | -$17.8M | N/A |
| Investing Cash Flow | $361.8M | $103.8M-21.2% | $131.7M+234.3% | -$98.1M-41.5% | -$69.3M-467.7% | $18.9M+119.5% | -$96.6M-147.6% | -$39.0M-640.0% | -$5.3M-593.7% | -$760K-126.9% | -$335K | N/A | N/A |
| Financing Cash Flow | $82K | $148K-99.9% | $185.7M-10.9% | $208.4M+34.2% | $155.3M+312.1% | $37.7M-86.7% | $283.0M+59.2% | $177.8M+15.8% | $153.5M+504.2% | $25.4M+158687.5% | $16K | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $72K | $0 | $0 | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RCKT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -80.5%-24.6pp | -55.9%-6.0pp | -49.9%-4.5pp | -45.3%-8.1pp | -37.2%-9.4pp | -27.7%-2.6pp | -25.1%+13.3pp | -38.4%+87.8pp | -126.2%-35.7pp | -90.5%+347.0pp | -437.5% | N/A |
| Return on Assets | -67.5%-18.5pp | -49.0%-5.7pp | -43.4%-3.2pp | -40.2%-6.2pp | -34.0%-10.4pp | -23.6%-2.9pp | -20.8%+8.9pp | -29.6%+67.5pp | -97.2%-91.3pp | -5.8%+54.1pp | -60.0%+112.7pp | -172.7% |
| Current Ratio | 6.38-2.9x | 9.30+1.5x | 7.80-1.5x | 9.29-8.4x | 17.69+2.7x | 14.94-1.9x | 16.81+3.2x | 13.60+9.4x | 4.19-14.0x | 18.23-8.9x | 27.14+26.6x | 0.51 |
| Debt-to-Equity | 0.19+0.1x | 0.140.0x | 0.150.0x | 0.130.0x | 0.09-0.1x | 0.170.0x | 0.21-0.1x | 0.300.0x | 0.30-14.2x | 14.49+8.2x | 6.29 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Rocket Pharmaceu Ranks
Frequently Asked Questions
What is Rocket Pharmaceu's annual revenue?
Rocket Pharmaceu (RCKT) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Rocket Pharmaceu profitable?
No, Rocket Pharmaceu (RCKT) reported a net income of -$223.1M in fiscal year 2025.
What is Rocket Pharmaceu's EBITDA?
Rocket Pharmaceu (RCKT) had EBITDA of -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rocket Pharmaceu's return on equity (ROE)?
Rocket Pharmaceu (RCKT) has a return on equity of -80.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rocket Pharmaceu's free cash flow?
Rocket Pharmaceu (RCKT) recorded an outflow of $190.5M in free cash flow during fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rocket Pharmaceu's operating cash flow?
Rocket Pharmaceu (RCKT) recorded an outflow of $190.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Rocket Pharmaceu's total assets?
Rocket Pharmaceu (RCKT) had $330.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Rocket Pharmaceu's capital expenditures?
Rocket Pharmaceu (RCKT) invested $440K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Rocket Pharmaceu spend on research and development?
Rocket Pharmaceu (RCKT) invested $142.0M in research and development during fiscal year 2025.
What is Rocket Pharmaceu's current ratio?
Rocket Pharmaceu (RCKT) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.
What is Rocket Pharmaceu's debt-to-equity ratio?
Rocket Pharmaceu (RCKT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rocket Pharmaceu's return on assets (ROA)?
Rocket Pharmaceu (RCKT) had a return on assets of -67.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rocket Pharmaceu's cash runway?
Based on fiscal year 2025 data, Rocket Pharmaceu (RCKT) had $77.6M in cash against an annual operating cash burn of $190.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rocket Pharmaceu's Altman Z-Score?
Rocket Pharmaceu (RCKT) has an Altman Z-Score of -3.49, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Rocket Pharmaceu's Piotroski F-Score?
Rocket Pharmaceu (RCKT) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rocket Pharmaceu's earnings high quality?
Rocket Pharmaceu (RCKT) reported a net loss of $223.1M while operations used $190.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Rocket Pharmaceu cover its interest payments?
Rocket Pharmaceu (RCKT) reported an operating loss of $231.7M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.